🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Thulium Laser and Growth Factors for Androgenetic Alopecia

RecruitingNAAges 18 Years - anyAllUniversitätsklinikum Hamburg-Eppendorf
NCT07079657 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Men and women aged 18 and over * Good general health, no relevant previous illnesses * Presence of an AGA * Cognitive ability and willingness to give consent (informed consent) * Be willing and able to attend follow-up visits Exclusion Criteria: * Age \< 18 years * Pregnant or breastfeeding women * Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs * Significant scarring of the region to be treated * Significant open wounds or lesions in the region to be treated * Metallic implants in the head region * Mental illnesses (psychoses, body perception disorders) * Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks * Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period * Tendency to excessive scarring * Lack of informed consent and/or data protection declarations
💊

What it tests

  • Thulium laser + growth factor serum + LED
  • Thulium laser + growth factor serum
  • Thulium laser
📍

Where

1 site
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy